Loading...
In patients with colorectal cancer, persistent circulating tumor DNA (ctDNA) after curative surgery is the strongest predictor of disease recurrence. To examine the interplay between ctDNA positivity, celecoxib treatment, and colorectal cancer outcomes, investigators conducted a post hoc analysis of the phase 3 CALGB (Alliance)/SWOG 80702 randomized trial. In the trial, 2500 patients with resected stage III colorectal cancer were assigned to either 3 or 6 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, and also to either celecoxib (400 mg) or placebo daily for 3 years. About one third of participants had valid ctDNA results, of whom 18% tested positive for post-surgical ctDNA.
Patients wh…